Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
On-target management for secondary hyperparathyroidism by two calcimimetics (HP2C study)
jRCTs051190014Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label trial of etelcalcetide and cinacalcet in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Achievement ratio for target levels of PTH, Ca, and P. Started Dec 2017; status: completed.
02
Drugs
etelcalcetidecinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCTs051190014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190014.